Shanghai Labway Clinical Laboratory Co., Ltd. (301060.SZ)
CNY 8.92
(-2.94%)
CNY 8.92
(-2.94%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -486.57 Million CNY | -7.19% |
| 2022 | -453.95 Million CNY | -58.58% |
| 2021 | -286.26 Million CNY | 16.69% |
| 2020 | -343.59 Million CNY | -33.35% |
| 2019 | -257.66 Million CNY | -47.07% |
| 2018 | -175.19 Million CNY | -150.48% |
| 2017 | -69.94 Million CNY | 57.52% |
| 2016 | -164.66 Million CNY | -465.04% |
| 2015 | -29.14 Million CNY | -73.89% |
| 2014 | -16.75 Million CNY | 38.28% |
| 2013 | -27.15 Million CNY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q3 | -392.95 Million CNY | -5.4% |
| 2024 Q2 | -372.81 Million CNY | 11.66% |
| 2024 Q1 | -422.03 Million CNY | 13.26% |
| 2023 Q1 | -505.88 Million CNY | -11.44% |
| 2023 FY | -486.57 Million CNY | -7.19% |
| 2023 Q4 | -486.57 Million CNY | -198.83% |
| 2023 Q3 | -162.82 Million CNY | 67.41% |
| 2023 Q2 | -499.68 Million CNY | 1.22% |
| 2022 FY | -453.95 Million CNY | -58.58% |
| 2022 Q3 | -169.27 Million CNY | 18.22% |
| 2022 Q2 | -206.97 Million CNY | -13.35% |
| 2022 Q4 | -453.95 Million CNY | -168.18% |
| 2022 Q1 | -182.6 Million CNY | 36.21% |
| 2021 Q1 | 532.71 Million CNY | 229.27% |
| 2021 Q3 | -286.33 Million CNY | -128.39% |
| 2021 Q4 | -286.26 Million CNY | 0.03% |
| 2021 FY | -286.26 Million CNY | 16.69% |
| 2021 Q2 | -125.36 Million CNY | -123.53% |
| 2020 Q4 | -412.08 Million CNY | 0.0% |
| 2020 Q1 | 485.31 Million CNY | 288.35% |
| 2020 FY | -343.59 Million CNY | -33.35% |
| 2020 Q2 | -195.98 Million CNY | -140.38% |
| 2020 Q3 | - CNY | 100.0% |
| 2019 FY | -257.66 Million CNY | -47.07% |
| 2019 Q4 | -257.66 Million CNY | 0.0% |
| 2018 FY | -175.19 Million CNY | -150.48% |
| 2017 Q1 | -427.31 Million CNY | -159.51% |
| 2017 Q2 | -427.31 Million CNY | 0.0% |
| 2017 FY | -69.94 Million CNY | 57.52% |
| 2016 Q1 | -101.2 Million CNY | -247.27% |
| 2016 Q2 | -101.2 Million CNY | 0.0% |
| 2016 FY | -164.66 Million CNY | -465.04% |
| 2016 Q3 | -164.66 Million CNY | -62.71% |
| 2016 Q4 | -164.66 Million CNY | 0.0% |
| 2015 Q4 | -29.14 Million CNY | 0.0% |
| 2015 Q3 | -29.14 Million CNY | 0.0% |
| 2015 Q1 | 36.75 Million CNY | 0.0% |
| 2015 FY | -29.14 Million CNY | -73.89% |
| 2014 FY | -16.75 Million CNY | 38.28% |
| 2013 FY | -27.15 Million CNY | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Dian Diagnostics Group Co.,Ltd. | 1.31 Billion CNY | 136.908% |
| Hangzhou Tigermed Consulting Co., Ltd. | -4.06 Billion CNY | 88.022% |
| Dirui Industrial Co.,Ltd. | -131.62 Million CNY | -269.68% |
| Beijing Strong Biotechnologies, Inc. | 411.59 Million CNY | 218.219% |
| Medicalsystem Biotechnology Co., Ltd. | -850.71 Million CNY | 42.803% |
| Maccura Biotechnology Co.Ltd | -170.79 Million CNY | -184.894% |
| Guangzhou Wondfo Biotech Co.,Ltd | -240.75 Million CNY | -102.103% |
| Guangdong Hybribio Biotech Co.,Ltd. | -708.27 Million CNY | 31.301% |
| BGI Genomics Co., Ltd. | -3.63 Billion CNY | 86.618% |
| Amoy Diagnostics Co., Ltd. | -92.73 Million CNY | -424.717% |